The front page of AI-driven biology
Friday, October 16, 2026Fri, Oct 16
Updated 1:02 AM PT
Clinical readouts, approvals, and setbacks, financing, dealmaking, platform progress, and reported research across biotech and biopharma, including the companies building AI into biology.
Novo Nordisk reported that 40% of pediatric participants receiving the GLP-1 receptor agonist Wegovy (semaglutide) were no longer classified as having obesity in a Phase 3 pediatric trial.
Amgen's bispecific T-cell engager Imdelltra (tarlatamab), which targets DLL3 to direct immune cells against tumors, demonstrated a statistically significant improvement in overall survival in a first-line small-cell lung cancer trial.